Integration of smoking cessation into standard treatment for patients receiving opioid agonist therapy who are smoking tobacco: protocol for a randomised controlled trial (ATLAS4LAR)

Karl Trygve Druckrey-Fiskaaen, Einar Furulund, Jan Tore Daltveit, Jørn Henrik Vold, Torgeir Gilje Lid, Tesfaye Madebo, Lars Thore Fadnes, ATLAS4LAR Study Group, Vibeke Bråthen Buljovcic, Trude Fondenes, Per Gundersen, Siv-Elin Leirvåg Carlsen, Mette Hegland Nordbotn, Marianne Cook Pierron, Christine Sundal, Jørn Henrik Vold, Maren Borsheim Bergsaker, Eivin Dahl, Tone Lise Eielsen, Torhild Fiskå, Eirik Holder, Tine Selmer Cruickshank, Ewa Joanna Wilk, Karl Trygve Druckrey-Fiskaaen, Einar Furulund, Jan Tore Daltveit, Jørn Henrik Vold, Torgeir Gilje Lid, Tesfaye Madebo, Lars Thore Fadnes, ATLAS4LAR Study Group, Vibeke Bråthen Buljovcic, Trude Fondenes, Per Gundersen, Siv-Elin Leirvåg Carlsen, Mette Hegland Nordbotn, Marianne Cook Pierron, Christine Sundal, Jørn Henrik Vold, Maren Borsheim Bergsaker, Eivin Dahl, Tone Lise Eielsen, Torhild Fiskå, Eirik Holder, Tine Selmer Cruickshank, Ewa Joanna Wilk

Abstract

Background: About 85% of patients receiving opioid agonist therapy (OAT) for opioid dependence are smoking tobacco. Although smoke-related pulmonary diseases are significant contributors to morbidity and mortality, few smoking cessation interventions are evaluated within this group, and few OAT patients are offered smoking cessation as an integrated part of their addiction treatment. This study protocol describes an integrated smoking cessation intervention aimed at patients receiving OAT and smoking tobacco.

Methods: This is a multicentre, randomised controlled clinical trial that will recruit 266 daily tobacco smoking patients receiving OAT in OAT outpatient clinics in Bergen and Stavanger, Norway. The patients randomised for the intervention arm will be offered smoking cessation therapy consisting of weekly brief behavioural interventions and prescription-free nicotine replacement products. In the control arm, patients will receive standard care without any added interventions related to smoking cessation. The smoking cessation intervention includes psychoeducational techniques with components from motivational interviewing, and nicotine replacement products such as nicotine lozenges, patches, and chewing gum. The duration of the intervention is 16 weeks, with the option of extending it by a further 8 weeks. The main outcomes are measured at 16 weeks after initiation of the intervention, and sustained effects are evaluated 1 year after intervention initiation. The primary outcome is smoking cessation verified by carbon monoxide (CO) levels or at least a 50% reduction in the number of cigarettes smoked. Secondary outcomes are changes in psychological well-being, biochemical inflammation markers, changes in physical health, quality of life, and fatigue.

Discussion: Integration of other treatments to standard OAT care improves adherence and completion rates providing another rationale for integrated smoking cessation treatment. Thus, if integrated smoking cessation treatment is superior to standard care, this trial provides important information on further scale-up.

Trial registration: ClinicalTrials.gov NCT05290025. Registered on 22 March 2022.

Keywords: Behavioural intervention; Nicotine replacement; Opiate substitution treatment; Smoking cessation; Substance abuse treatment centres.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Timeline for nicotine replacement therapy component of the smoking cessation intervention. Remarks: The blue columns indicate evaluation points

References

    1. Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, Burnett R, Casey D, Coates MM, Cohen A, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(10010):2287–2323. doi: 10.1016/S0140-6736(15)00128-2.
    1. Collaborators GBDCoD Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–1788. doi: 10.1016/S0140-6736(18)32203-7.
    1. Inoue-Choi M, Christensen CH, Rostron BL, Cosgrove CM, Reyes-Guzman C, Apelberg B, Freedman ND. Dose-response association of low-intensity and nondaily smoking with mortality in the United States. JAMA Netw Open. 2020;3(6):e206436. doi: 10.1001/jamanetworkopen.2020.6436.
    1. Inoue-Choi M, Hartge P, Park Y, Abnet CC, Freedman ND. Association between reductions of number of cigarettes smoked per day and mortality among older adults in the United States. Am J Epidemiol. 2019;188(2):363–371. doi: 10.1093/aje/kwy227.
    1. Hayes RD, Chang CK, Fernandes A, Broadbent M, Lee W, Hotopf M, Stewart R. Associations between substance use disorder sub-groups, life expectancy and all-cause mortality in a large British specialist mental healthcare service. Drug Alcohol Depend. 2011;118(1):56–61. doi: 10.1016/j.drugalcdep.2011.02.021.
    1. Lewer D, Jones NR, Hickman M, Nielsen S, Degenhardt L. Life expectancy of people who are dependent on opioids: a cohort study in New South Wales, Australia. J Psychiatr Res. 2020;130:435–440. doi: 10.1016/j.jpsychires.2020.08.013.
    1. Rehm J, Manthey J, Shield KD, Ferreira-Borges C. Trends in substance use and in the attributable burden of disease and mortality in the WHO European Region, 2010-16. Eur J Public Health. 2019;29(4):723–728. doi: 10.1093/eurpub/ckz064.
    1. Westman J, Wahlbeck K, Laursen TM, Gissler M, Nordentoft M, Hällgren J, Arffman M, Ösby U. Mortality and life expectancy of people with alcohol use disorder in Denmark, Finland and Sweden. Acta Psychiatr Scand. 2015;131(4):297–306. doi: 10.1111/acps.12330.
    1. Aas CF, Vold JH, Skurtveit S, Lim AG, Ruths S, Islam K, Askildsen JE, Løberg EM, Fadnes LT, Johansson KA. Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway. Subst Abuse Treat Prev Policy. 2020;15(1):68. doi: 10.1186/s13011-020-00309-y.
    1. Guydish J, Passalacqua E, Pagano A, Martinez C, Le T, Chun J, Tajima B, Docto L, Garina D, Delucchi K. An international systematic review of smoking prevalence in addiction treatment. Addiction. 2016;111(2):220–230. doi: 10.1111/add.13099.
    1. Bech AB, Clausen T, Waal H, Delaveris GJM, Skeie I. Organ pathologies detected post-mortem in patients receiving opioid agonist treatment for opioid use disorder: a nation-wide 2-year cross-sectional study. Addiction. 2022;117(4):977–985. doi: 10.1111/add.15705.
    1. Mehta S, Parmar N, Kelleher M, Jolley CJ, White P, Durbaba S, Ashworth M. COPD and asthma in patients with opioid dependency: a cross-sectional study in primary care. NPJ Prim Care Respir Med. 2020;30(1):4. doi: 10.1038/s41533-019-0161-7.
    1. Apollonio D, Philipps R, Bero L. Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database Syst Rev. 2016;11:CD010274.
    1. Guydish J, Kapiteni K, Le T, Campbell B, Pinsker E, Delucchi K. Tobacco use and tobacco services in California substance use treatment programs. Drug Alcohol Depend. 2020;214:108173. doi: 10.1016/j.drugalcdep.2020.108173.
    1. Vlad C, Arnsten JH, Nahvi S. Achieving smoking cessation among persons with opioid use disorder. CNS Drugs. 2020;34(4):367–387. doi: 10.1007/s40263-020-00701-z.
    1. Yee A, Hoong MC, Joyce YC, Loh HS. Smoking cessation among methadone-maintained patients: a meta-analysis. Subst Use Misuse. 2018;53(2):276–285. doi: 10.1080/10826084.2017.1342661.
    1. Notley C, Gentry S, Livingstone-Banks J, Bauld L, Perera R, Hartmann-Boyce J. Incentives for smoking cessation. Cochrane Database Syst Rev. 2019;7(7):CD004307.
    1. Lindson-Hawley N, Thompson TP, Begh R. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev. 2015;3:CD006936.
    1. Patnode CD, Henderson JT, Coppola EL, Melnikow J, Durbin S, Thomas RG. Interventions for tobacco cessation in adults, including pregnant persons: updated evidence report and systematic review for the US Preventive Services Task Force. Jama. 2021;325(3):280–298. doi: 10.1001/jama.2020.23541.
    1. Park ER, Perez GK, Regan S, Muzikansky A, Levy DE, Temel JS, Rigotti NA, Pirl WF, Irwin KE, Partridge AH, et al. Effect of sustained smoking cessation counseling and provision of medication vs shorter-term counseling and medication advice on smoking abstinence in patients recently diagnosed with cancer: a randomized clinical trial. Jama. 2020;324(14):1406–1418. doi: 10.1001/jama.2020.14581.
    1. Hall SM, Humfleet GL, Gasper JJ, Delucchi KL, Hersh DF, Guydish JR. Cigarette smoking cessation intervention for buprenorphine treatment patients. Nicotine Tob Res. 2018;20(5):628–635. doi: 10.1093/ntr/ntx113.
    1. Strand BH, Dalgard OS, Tambs K, Rognerud M. Measuring the mental health status of the Norwegian population: a comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36) Nord J Psychiatry. 2003;57(2):113–118. doi: 10.1080/08039480310000932.
    1. Vieira EB, Degani-Costa LH, Amorim BC, Oliveira LB, Miranda-Silva T, Sperandio PC, Medeiros WM, Arbex FF, Ramos RP, Nery LE. Modified BODE index to predict mortality in individuals with COPD: the role of 4-min step test. Respir Care. 2020;65(7):977–983. doi: 10.4187/respcare.06991.
    1. Peak J, Goranitis I, Day E, Copello A, Freemantle N, Frew E. Predicting health-related quality of life (EQ-5D-5 L) and capability wellbeing (ICECAP-A) in the context of opiate dependence using routine clinical outcome measures: CORE-OM, LDQ and TOP. Health Qual Life Outcomes. 2018;16(1):106. doi: 10.1186/s12955-018-0926-7.
    1. Vold JH, Gjestad R, Aas CF, Meland E, Johansson KA, Fadnes LT. Validation of a three-item Fatigue Severity Scale for patients with substance use disorder: a cohort study from Norway for the period 2016-2020. Health Qual Life Outcomes. 2021;19(1):69. doi: 10.1186/s12955-021-01708-w.
    1. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(4):1185–1189. doi: 10.1164/ajrccm.158.4.9802091.
    1. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381–1395. doi: 10.1249/01.MSS.0000078924.61453.FB.
    1. Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT, Hunn A, Bottomley A, Regnault A, Chan AW, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. Jama. 2018;319(5):483–494. doi: 10.1001/jama.2017.21903.
    1. Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. Bmj. 2017;359:j5085. doi: 10.1136/bmj.j5085.
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357(9263):1191–1194. doi: 10.1016/S0140-6736(00)04337-3.
    1. Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5(5):Cd000146.
    1. Nahvi S, Adams TR, Ning Y, Zhang C, Arnsten JH. Effect of varenicline directly observed therapy versus varenicline self-administered therapy on varenicline adherence and smoking cessation in methadone-maintained smokers: a randomized controlled trial. Addiction. 2021;116(4):902–913. doi: 10.1111/add.15240.
    1. Fadnes LT, Aas CF, Vold JH, Leiva RA, Ohldieck C, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, et al. Integrated treatment of hepatitis C virus infection among people who inject drugs: a multicenter randomized controlled trial (INTRO-HCV) PLoS Med. 2021;18(6):e1003653. doi: 10.1371/journal.pmed.1003653.
    1. Vijayaraghavan M, Elser H, Frazer K, Lindson N, Apollonio D. Interventions to reduce tobacco use in people experiencing homelessness. Cochrane Database Syst Rev. 2020;12(12):CD013413.
    1. Committee for Human Medicinal Products. Guideline for good clinical practice E6(R2) 6 edn. European Medicines Agency. 2018. . Accessed 1 May 2022
    1. Environment Directorate Chemicals Group And Management Committee. OECD Principles on Good Laboratory Practice. Organisation for Economic Co-operation and Development. 1998. . Accessed 1 May 2022

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅